ClinicalTrials.gg
RecruitingNCT06411054Updated May 12, 2026

The Efficacy of Acu-TENS as an Adjunct Analgesic During USG-MVA

An interventional study of Acu-TENS and Sham acu-TENS in Pain, Acute, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Acute Pain with a site in Hong Kong — 4 open to participants now, 4 under way, none of them phase 3. Acute Pain · Hong Kong.

Planned enrollment
4th of 13
108 · median 90
Started
2024
with 2 others
No phase
5 of 16
3 open now
Registered
15th of 16
by date
Lead sponsor
3 of 16
Chinese University of Hong Kong

Among the 16 studies in Acute Pain with a site in Hong Kong, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 with no phase, and was the 15th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

4 of the 16 studies in Acute Pain with a site in Hong Kong are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Acute Pain with a site in Hong Kong, or all of them as a file.
02

Study summary

Objectives: To prospectively evaluate the potential of acu-TENS to reduce the pain experienced by women undergoing ultrasound-guided manual vacuum aspiration (USG-MVA) and evaluate its safety profile.

Hypothesis to be tested: Does the use of acu-TENS reduce pain in women undergoing USG-MVA?

Design and subjects: A prospective randomized control trial will be carried out at the Department of Obstetrics and Gynaecology of the Prince of Wales Hospital. Women undergoing USG-MVA for the treatment of early pregnancy loss before 12 weeks of gestation will be randomized to receive acu-TENS (intervention group) or sham acu-TENS (control group) for pain control during USG-MVA. We will recruit 54 participants in each of the two arms, so a total of 108 patients will be recruited.

Study instruments: USG-MVA will be performed using a 60ml charged syringe (MedGyn Aspiration Kit) with a flexible curette attached to it. Transabdominal ultrasound during the MVA procedure will be performed using Mindray DC-80A Diagnostic Ultrasound System. Acu-TENS will be performed using MTR+ Myolito Multifunctional Stimulator (MTRP-00003).

Main outcome measures: Primary outcome includes pain scores before, during and after USG-MVA. Secondary outcomes include (1) stress levels measured by heart rate, heart rate variability, blood pressure, State Trait Anxiety Inventory (STAI), and salivary cortisol; (2) anxiety level; (3) Surgeon's assessment on the patient co-operation score and patient intraoperative pain, (4) Client Satisfaction Questionnaire (CSQ8) and satisfaction score, and (5) any adverse events of acu-TENS.

Data analysis: Data analysis will be performed using the Statistical Packages of Social Sciences for Windows (SPSS, Inc).

Expected results: We expect that acu-TENS will result in at least a 35% reduction in pain experienced by women undergoing USG-MVA.

Read the detailed description

Randomization process and blinding of clinician For those who consented to the study, they will be randomly assigned preoperatively to receive "acu-TENS" or "sham acu-TENS" according to a computer-generated random number series by an independent research nurse who is not in our team in a 1:1 ratio. Prior to the onset of the study, sequentially numbered (written on top) non-opaque envelopes containing treatment modality, (i) intervention group (Group A): acu-TENS in USG-MVA (ii) controlled group (Group B): sham acu-TENS in USG-MVA will be also prepared by an independent research nurse. On opening the envelope, the study nurse will record the envelope number and the randomization group assigned in patient recruitment password protected electronic file. The assigned envelope number will then be documented in a second electronic password protected file which will be used to document procedure details, patients' details, procedure outcome and investigation assessments.

The Firstbeat Body-guard 3 device to measure HRV will be applied 1 hour before the procedure and will remain in place for 1 hour after the procedure.

15 minutes before MVA, after the clinician has applied the TENS pads on specific acupoints, and connected the pads to the TENS machine, the study nurse will be responsible to (i) intervention group (Group A): turn on the TENS machine or (ii) controlled group (Group B): pretend to turn on the TENS machine. 15 minutes after MVA, the study nurse will (i) intervention group (Group A): turn off the TENS machine or (ii) controlled group (Group B): pretend to turn off the TENS machine. After that, the clinician will disconnect the wires and remove the pads. Hence, the clinician will be blinded throughout the process.

The study nurse will not be present during the operative procedure, nor will she be involved in the any investigations. Moreover, another team of gynaecologist and nursing staff will help with the follow-up phone calls to avoid performance and measurement biases and the problem of automatic unblinding.

USG-MVA procedure All women will be asked to fill in the STAI questionnaire before they come to hospital. Once admitted, all women will be given 400µg of misoprostol orally for cervical priming, 2-3 hours before the procedure. 500mg of naproxen will be given 60 min before the procedure. Paracetamol or codeine will be used as an alternative to naproxen in case of allergy.

The USG-MVA procedure will be carried out by doctors with similar surgical experience who have carried out at least 25 USG-MVA procedures independently. The USG-MVA will be carried out using a 60-ml charged syringe (MedGyn Aspiration Kit IV, 022511) (Addison, IL, USA) with a flexible curette (size 4-7 mm, subject to the doctor's discretion) attached to it. Paracervical block will be carried out using a 23-gauge dental needle syringe to inject 5 ml of 2% lidocaine into a depth of 0.5 cm at the cervical-vaginal juncture at 4, 5, 7 and 8 o'clock position to reach the uterosacral ligaments. A tenaculum will be used to hold the cervix if necessary. Voluson E730 Expert USG system will be used for transabdominal USG during MVA. During the procedure, 5-ml of local lidocaine gel will be applied to the cervical canal and over the end of the MVA catheter tip during the insertion. A research assistant will help the patient with filling in an intra-procedure VAS questionnaire.

The USG-MVA procedure will be stopped as soon as the operating clinician is satisfied that the uterine cavity is empty. Products of conception will be sent for histological evaluation and cytogenetic analysis if clinically indicated. Postoperative complications, including significant bleeding requiring blood transfusion, uterine perforation and infection and side-effects such as nausea, vomiting, dizziness, drowsiness, shortness of breath and dry mouth or eyes from the medication and their severity will be documented.

Acu-TENS treatment and Sham acu-TENS treatment All acu-TENS and sham acu-TENS treatments will be performed on site in the same manner by a clinician who follows a standard approach to describe the intervention to participants.

After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTR+ Myolito Multifunctional Stimulator MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).

In the sham acu-TENS group, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current.

Measurement of Pain Individual pain scores, measured by the visual analog scale (VAS), is recorded before taking misoprostol, right before the surgery, during (during cannula insertion, and for every suction), and after USG-MVA (0 min, 15 min, 30 min, and 1-hour post-MVA). Women will be asked to move the cursor along the VAS ruler, which does not have markings other than '0' and '10', to indicate her pain level at different time intervals. With a change of more than or equal to 10 for the 100 mm VAS, the analgesic intervention is clinical important.

To validate the VAS pain score rated by patients, surgeons will rate the patient compliance index and patient pain score. For the patient compliance index, it is a 5-point Likert scale rated from 1 (fully co-operation) to 5 (no co-operation, procedure abandoned).For the patient pain score, it is a 5-point Likert scale rated from 0 (patient did not show any sign of pain) to 4 (patient did not let the procedure continue which was demonstrated by verbal or bodily expression).

Measurement of stress

  1. Blood pressure will be recorded before taking misoprostol, right before the surgery, during (during cannula insertion, and for every suction), and after USG-MVA (0 min, 15 min, 30 min, and 1-hour post-MVA).
  2. Heart rate and HRV one hour before USG-MVA to one hour after USG-MVA will be measured using Firstbeat Bodyguard 3 devices. Studies have shown that in acute pain, with ascending nociception, segmental spinal reflexes are recruited to activate the sympathetic system, resulting in increased peripheral resistance, heart rate, and stroke volume). HRV is a non-invasive measurement of the variation in time between consecutive heartbeats which provides information about the balance between the sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) branches of the autonomic nervous system. Under high stress, amygdala activation initiates the hypothalamic-pituitary-adrenal axis (HPA axis) response and parasympathetic withdrawal. This enhanced stress load is expressed as decreased cardiac vagal activity. HRV has also been found to be a useful in evaluating pain response and can potentially overcome some of the challenges of quantifying pain.
  3. Saliva will be collected for cortisol analysis before, immediately after, and 15 minutes after MVA. Cortisol is a stress hormone. We test the cortisol level in saliva instead of blood to avoid the stress brought by blood drawing which will result in elevated cortisol levels. Studies indicate elevated saliva cortisol levels in pain, for example, fibromyalgia and myofascial pain. Vice versa, when pain is relieved, saliva cortisol level will decrease. For example, pain is relieved by dance and yoga in functional abdominal pain disorders.
  4. Participants will be asked to fill in the STAI questionnaire before and after USG-MVA. STAI is a 40-items scale which used 4-point Likert scale ranged from almost never to almost always. The higher scoring indicates greater level of anxiety. It consists of two parts, the S-AD questionnaire for stress level and the T-AI questionnaire for traits. The validated Chinese version of STAI was used to measure the changing psychological status before and after USG-guided MVA, with a score ranging from 20 to 80. Participants will be asked to fill in both parts when they arrived at the hospital. This can give a better baseline anxiety index. A stress state may affect the pain level. Hence, after the USG-MVA procedure, the S-AD questionnaire will be done again.

Measurement of anxiety Participants will be asked to rate the VAS-anxiety before and after the USG-MVA procedure.

Measurement of patient satisfaction Participants will be asked to complete a client satisfaction questionnaire (CSQ8) after USG-MVA. CSQ8 contains eight items including the concern of quality of service, kind of service, outcome of service, extent in meeting their need, recommendation to friend, amount of help, effectiveness in dealing the problem, overall satisfaction and willingness to use the service again. It is rated by four-point Likert scale, which scores ranged from 8 to 32. The higher scores indicate greater satisfaction with the service or treatment. Participants will also be asked to rate their satisfaction on the MVA service from 0 score (lowest satisfaction) to 100 score (highest satisfaction) by a 100mm scale.

Recording the safety profile and potential benefits Follow-up phone calls will be made 1 month after the procedure to ask for possible side effects. Any serious adverse effects will be recorded.

03

Conditions studied

  • Pain, Acute

Browse trials for

Keywords

  • Manual vacuum aspiration
  • Ultrasound-guided
  • Acupuncture transcutaneous electrical nerve stimulation
  • Alternative medicine
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 or above;
  2. Patient diagnosed with first-trimester miscarriage, who is eligible for USG-MVA;
  3. Patient diagnosed with incomplete miscarriage after medical treatment;
  4. Willing to be randomized to receive acupuncture.

Exclusion criteria

Exclusion criteria

a. Patient not eligible for USG-MVA i. Miscarriage > 12 weeks of gestation; or ii. Pregnancy of unknown origin; or iii. Known narrowing of the cervical canal; or iv. Multiple uterine fibroids; or v. Congenital uterine anomalies; or vi. Active pelvic infection; or vii. Bleeding disorder; or viii. Inability to tolerate pelvic examination; or ix. History of allergy to misoprostol

b. Patient not eligible for acu-TENS i. Poor skin integrity at the acupuncture site, such as open wound, infections, unknown mass, bleeding tendency; or ii. Allergic to external alcohol; or iii. Emotionally unstable or tend to restlessness (to avoid tear-off of pads).

c. Patient refusal

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Au-TENS group

    Women will receive acu-TENS from 15 minutes before USG-MVA to 15 minutes after USG-MVA.

    Device: Acu-TENS

  • Sham comparator
    Sham acu-TENS group

    Women will receive sham acu-TENS from 15 minutes before USG-MVA to 15 minutes after USG-MVA. In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current.

    Device: Sham acu-TENS

Interventions

  • DeviceAcu-TENS

    After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).

  • DeviceSham acu-TENS

    After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current. The pads will be stuck on the acupoints for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).

06

What researchers measure

Primary outcomes

  1. VAS pain score

    Women will be asked to move the cursor along the VAS ruler, which does not have markings other than '0' and '10', to indicate her pain level at different time intervals. With a change of more than or equal to 10 for the 100 mm VAS, the analgesic intervention is clinical important (Myles et al., 2017).

    Time frame: Before taking misoprostol, right before the surgery, during (during cannula insertion, and for every suction), and after USG-MVA (0 minutes, 15 minutes, 30 minutes, and 1-hour post-USG-MVA)

Secondary outcomes

  1. Stress level measured by STAI questionnaire

    STAI is a 40-items scale which used 4 point Likert scale ranged from almost never to almost always. It consists of two parts, the S-AD questionnaire for stress level and the T-AI questionnaire for traits. The validated Chinese version of STAI was used to measure the changing psychological status before and after USG-guided MVA, with a score ranging from 20 to 80.

    Time frame: 2 hours before and 1 hour after USG-MVA

  2. Stress level measured by saliva cortisol

    We test the cortisol level in saliva instead of blood to avoid the stress brought by blood drawing which will result in elevated cortisol levels. Studies indicate elevated saliva cortisol levels in pain, for example, chronic widespread pain or fibromyalgia(Begum et al., 2022), and myofascial pain(Nadendla et al., 2014). Vice versa, when pain is relieved, saliva cortisol level will decrease. For example, pain is relieved by dance and yoga in functional abdominal pain disorders(Areskoug Sandberg et al., 2022).

    Time frame: 2 hours before, right after, and 30 minutes after USG-MVA

  3. VAS Anxiety Score

    Women will be asked to move the cursor along the VAS ruler, which does not have markings other than '0' and '10', to indicate her pain level at different time intervals.

    Time frame: Before taking misoprostol, right before the surgery, during (during cannula insertion, and for every suction), and after USG-MVA (0 minutes, 15 minutes, 30 minutes, and 1-hour post-USG-MVA)

  4. Blood pressure

    Studies have shown that in acute pain, with ascending nociception, segmental spinal reflexes are recruited to activate the sympathetic system, resulting in increased peripheral resistance, heart rate, and stroke volume(Bruehl et al., 2010; Fagius et al., 1989; Saccò et al., 2013(Bruehl et al., 2002)).

    Time frame: Before taking misoprostol, right before the surgery, during (during cannula insertion, and for every suction), and after USG-MVA (0 minutes, 15 minutes, 30 minutes, and 1-hour post-USG-MVA)

  5. Heart rate and heart rate variability

    Studies have shown that in acute pain, with ascending nociception, segmental spinal reflexes are recruited to activate the sympathetic system, resulting in increased peripheral resistance, heart rate, and stroke volume(Bruehl et al., 2010; Fagius et al., 1989; Saccò et al., 2013(Bruehl et al., 2002)).

    Time frame: One hour before USG-MVA to one hour after USG-MVA

  6. Patient Satisfaction Score

    Participants will also be asked to rate their satisfaction on the MVA service from 0 score (lowest satisfaction) to 100 score (highest satisfaction) by a 100mm scale.

    Time frame: One hour after USG-MVA

  7. Client satisfaction questionnaire (CSQ8)

    CSQ8 contains eight items including the concern of quality of service, kind of service, outcome of service, extent in meeting their need, recommendation to friend, amount of help, effectiveness in dealing the problem, overall satisfaction and willingness to use the service again. It is rated by four-point Likert scale, which scores ranged from 8 to 32. The higher scores indicate greater satisfaction with the service or treatment.

    Time frame: One hour after USG-MVA

  8. Patient compliance index

    To validate the VAS pain score rated by patients, surgeons will rate the patient compliance index. It is a 5-point Likert scale rated from 1 (fully co-operation) to 5 (no co-operation, procedure abandoned).

    Time frame: Right after USG-MVA

  9. Patient pain score

    To validate the VAS pain score rated by patients, surgeons will rate the patient pain score. It is a 5-point Likert scale rated from 0 (patient did not show any sign of pain) to 4 (patient did not let the procedure continue which was demonstrated by verbal or bodily expression).

    Time frame: Right after USG-MVA

  10. Potential benefits

    Pregnancy outcomes, information collected by phone calls

    Time frame: 1 year post USG-MVA

  11. Adverse events

    Information collected by phone calls

    Time frame: 1 month post USG-MVA

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 38 months is above that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 13, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 31, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06411054
Responsible party
Chung Pui Wah Jacqueline (Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
May 13, 2024
Start date
Jun 1, 2024
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion